Natco Pharma has clarified that they made all necessary disclosures pursuant to Regulation 30 of SEBI (LODR) Regulations, 2015, that have bearing on the operations/performance of the Company which include all the price sensitive information and has not withheld any material/ price sensitive information that in its opinion would have bearing on the volume behaviour of the Shares. Therefore, the said increase in volume of shares of the Company is purely market driven and due to market conditions.
The above information is a part of company’s filings submitted to BSE.
